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NeuroML version 1.x allows specification of detailed cell
and network models incorporating complex neuronal
morphologies, voltage and ligand-gated ion channels,
fixed and plastic synapses, and positioning and connec-
tivity of cell populations in 3D [1]. An increasing
number of freely available software packages support
this version of NeuroML (http://www.neuroml.org/
tool_support) and published cell and network models
from the neocortex, cerebellum and hippocampus have
been converted to the format. While the focus of
NeuroML v1.x was on (multicompartmental) conduc-
tance based neuronal models, networks incorporating
simplified neurons are widely used to investigate proper-
ties of neuronal systems [2]. These network models can
be created from multiple (hierarchical) population sets
with complex connectivity. At the other end of the bio-
logical scale an increasing amount of modelling work
incorporates detailed subcellular signalling pathways,
especially for investigating synaptic plasticity [3]. These
points have been the motivation for version 2.0 of the
language.
A tt h ec o r eo fN e u r o M Lv e r s i o n2 . 0i st h eL E M S
(Low Entropy Model Specification) language. This
allows Component Types to be specified which define
the behaviour of Components to be used in simulations.
A Component Type consists of a number of state vari-
ables and a specification of their dynamical behaviour in
terms of a set of parameters. LEMS can express a wide
range of dynamical models and NeuroML v2.0 will
describe a core set of neuroscience specific Component
Types. Current examples supported include abstract
cells (e.g. I&F, Izhikevich, Adaptive Exponential I&F,
FitzHugh-Nagumo), ion channels (HH, kinetic scheme
based, ligand gated) and synapse models (AMPA/
NMDA mediated, STP, STDP). Supporting software can
handle these types natively, or support the full LEMS
framework. A package for parsing LEMS is available
(http://www.neuroml.org/lems), which can natively run
simulations of networks of single compartment cells.
This also supports export of the model in a number of
formats, including NEURON, which facilitates executing
multicompartmental cell models expressed in NeuroML
v2.0. SBML files can also be generated from LEMS, and
an import option is being developed to allow the bio-
chemical signalling models in the BioModels database to
be used with LEMS/NeuroML 2.0. An updated scheme
for specifying templates for hierarchical networks has
been developed and this representation, together with
abstract cell models, can be exported in the emerging
NineML format.
NeuroML 2.0 will encompass all functionality from v1.
x, with automatic update of models possible through
neuroConstruct [4] . This will make all existing detailed
models available in the new version of the language.
The development process for NeuroML is open to all
and contributions are welcome from across the commu-
nity (see http://www.neuroml.org/neuroml2). This work
will facilitate the exchange of models and ideas between
theoreticians, modellers and experimentalists across the
neuroscience and wider systems biology communities. * Correspondence: p.gleeson@ucl.ac.uk
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